Volume 14, Number 2—February 2008
Research
Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic
M. Ruby Siddiqui*
and W. John Edmunds*
and W. John Edmunds*
Figure 3
![Univariate sensitivity analyses of the incremental cost-effectiveness of the test-treat strategy over the treat only strategy to A) near-test sensitivity and specificity and B) near-test unit cost and shelf-life. The test-treat program becomes cost-effective below the cost-effectiveness threshold (£30,000 per quality-adjusted life year [QALY] gained).](/eid/images/07-0478-F3.jpg "Figure 3. Univariate sensitivity analyses of the incremental cost-effectiveness of the test-treat strategy over the treat only strategy to A) near-test sensitivity and specificity and B) near-test unit cost and shelf-life. The test-treat program becomes cost-effective below the cost-effectiveness threshold (£30,000 per quality-adjusted life year [QALY] gained).")
Figure 3. Univariate sensitivity analyses of the incremental cost-effectiveness of the test-treat strategy over the treat only strategy to A) near-test sensitivity and specificity and B) near-test unit cost and shelf-life. The test-treat program becomes cost-effective below the cost-effectiveness threshold (£30,000 per quality-adjusted life year [QALY] gained).
Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Content Credential
